Next Article in Journal
Differential Expression of Kinin Receptors in Human Wet and Dry Age-Related Macular Degeneration Retinae
Previous Article in Journal
Multi-Step Ubiquitin Decoding Mechanism for Proteasomal Degradation
Previous Article in Special Issue
Anticancer Activity of Amb4269951, a Choline Transporter-Like Protein 1 Inhibitor, in Human Glioma Cells
Open AccessArticle

Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results

1
The Graduate Studies Authority, University of Haifa, Haifa 31000, Israel
2
School of Social Work, University of Haifa, Haifa 31000, Israel
3
Clinical Immunology and Tissue Typing Lab, Rambam Medical Center, Haifa 31000, Israel
4
Division of Oncology, Rambam Health Care Campus, Haifa 31000, Israel
5
Hematology and Bone Marrow Transplantation, Sourasky Medical Center, Tel Aviv 6423906, Israel
6
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31000, Israel
7
Cancer Center, Emek Medical Center, 21 Yitzhak Rabin Blvd., Afula 1834111, Israel
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(6), 129; https://doi.org/10.3390/ph13060129
Received: 4 May 2020 / Revised: 14 June 2020 / Accepted: 19 June 2020 / Published: 23 June 2020
(This article belongs to the Special Issue Supportive and Palliative Cancer Treatment)
Adjuvant chemotherapy is recommended in high-risk stage II–III colorectal cancer (CC). We examine the effect of daily wheatgrass juice (WGJ) intake in addition to chemotherapy on immune parameters, including IL-6, IL-8, IL-10, IL-12, and white blood cells (WBCs) among CC patients. In a controlled prospective trial, 100 stage II–III CC patients were enrolled. According to patient preference, they were divided into two subgroups, control group and intervention group, 50 patients each, all of whom received the same standard postoperative adjuvant chemotherapy, plus consumption of 60 cc WGJ daily in the intervention group. Blood samples were collected at baseline (T0) and upon treatment termination, 5–6 months later (T1). Cytokine concentrations were assessed using ELISA kits. Anti-inflammatory cytokine IL-10 concentrations were significantly higher in the WGJ group than in the control group at T1. The decline in WBC counts between T0 and T1 was significantly lower in the WGJ group. No significant differences were observed in IL-6, IL-8, and IL-12 concentrations between the study groups. The higher levels of IL-10 and the attenuating of WBC decline during chemotherapy may constitute preliminary evidence of the beneficial effects of WGJ on immune parameters, when given as a supplement to standard care. In light of these preliminary results, WGJ supports immunological parameters during adjuvant chemotherapy. Nevertheless, future studies are needed in order to translate those results to clinical recommendations for cancer survivors. View Full-Text
Keywords: colon cancer (CC); adjuvant chemotherapy; wheatgrass; immune measures colon cancer (CC); adjuvant chemotherapy; wheatgrass; immune measures
Show Figures

Graphical abstract

MDPI and ACS Style

Avisar, A.; Cohen, M.; Katz, R.; Shentzer Kutiel, T.; Aharon, A.; Bar-Sela, G. Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results. Pharmaceuticals 2020, 13, 129.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop